In the latest move to cement its “immunology powerhouse” status, Sanofi is handing ove | The CD20-directed antibody, dubbed ...

Sanofi SNY announced that it signed an agreement with California-based privately held biopharmaceutical company Dren Bio to ...

Sanofi and Regeneron have been collaborating since 2003, with the partnership generating some of Sanofi’s most prominent drugs including top-selling Dupixent (dupilumab) for eczema and asthma ...

Sanofi’s move for Dren Bio’s clinical asset boosts its immunology-focused strategy of becoming a leader in the field.

The deal is the latest in a series of Sanofi investments in its immunology portfolio. According to Sanfoi, DR-0201 can ...

Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) presented positive results from the pivotal ADEPT Phase 2/3 trial evaluating the ...

Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for ...

The Dermatology Foundation (DF) and the Skin of Color Society (SOCS) announce that Crystal U. Aguh, MD, FAAD, is the 2025 ...

The appeals court for the Federal Circuit upheld a lower court’s ruling, finding that Regeneron has not sufficiently ...

This health education program aims to help patients living with COPD experience better health outcomes and improved quality of life for the duration of their lives.

Goldman Sachs analyst James Quigley upgraded Sanofi (SNYNF – Research Report) to a Hold today and set a price target of €120.00. The company’s ...

Amgen’s $400 million eczema drug candidate has recorded two more phase 3 victories. The data drops provide more evidence that ...